An Absolute Bioavailability Study of Baricitinib in Healthy Subjects Using the Intravenous Tracer Method

Trial Profile

An Absolute Bioavailability Study of Baricitinib in Healthy Subjects Using the Intravenous Tracer Method

Completed
Phase of Trial: Phase I

Latest Information Update: 25 Feb 2015

At a glance

  • Drugs Baricitinib (Primary) ; Baricitinib (Primary)
  • Indications Diabetic nephropathies; Psoriasis; Rheumatoid arthritis
  • Focus Pharmacokinetics
  • Sponsors Eli Lilly
  • Most Recent Events

    • 19 Feb 2015 Status changed from recruiting to completed as reported by ClinicalTrials.gov record.
    • 21 Jan 2015 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.
    • 20 Jan 2015 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top